Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person7
Frazier Life Sciences Public Fund, L.P.
Company
Bain Capital Life Sciences Fund, L.P.
Company
Frazier Life Sciences Acquisition Corp. II
Company
Wave Life Sciences, Inc.
Company
ENDRA Life Sciences Inc.
Company
Caris Life Sciences, Inc.
Company
Emmaus Life Sciences, Inc.
Company
Primary record13
Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13D/A
(the "SEC") on October 29, 2026. 0001879466 N FHMLSP, L.P. b AF N DE 0.00 5323356.00 0.00 5323356.00 5323356.00 N 6.5 PN The shares listed in rows 8, 10 and 11 do not include any warrants held by the Reporting Person. Se
Frazier Life Sciences Acquisition Corp. II filed SCHEDULE 13D
pursuant to Rule 424(b)(4) on October 14, 2026. Each of Dr. Cha, as the sole manager of the Sponsor; FLSPF, as the sole equity holder of the Sponsor; FHMLSP, L.P., as the sole general partner of FLSPF; and FHMLSP, L.L.C.
Maze Therapeutics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. The information contained below under Item 3.02 is hereby incorporated by reference in response to this Item 1.01 of Form 8-K. Item 3.02. Unregistered Sales of Equity
Frazier Life Sciences Acquisition Corp. II filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On October 13, 2026, the Registration Statement on Form S-1 (File No. 333-299101) (the Registration Statement ) relating to the initial public offering (the IPO ) of
Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G
0001231919-26-001441.txt : 20261009 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001863769 XXXXXXXX LIVE Common Stock, $0.00001 par value 10/02/2026 0001661998 Q32 Bio Inc. 746964105 830 Winter Street Waltham MA 02
NewAmsterdam Pharma Co N.V. filed SCHEDULE 13D/A
0001231919-26-001215.txt : 20260922 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001790879 XXXXXXXX LIVE 7 Ordinary Shares, nominal value EUR0.12 per share 09/18/2026 false 0001936258 N62509109 NEWAMSTERDAM PHA
Aclaris Therapeutics, Inc. filed SCHEDULE 13G
0001231919-26-001199.txt : 20260921 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001863769 XXXXXXXX LIVE Common Stock, $0.00001 par value 09/14/2026 0001557746 ACLARIS THERAPEUTICS, INC. 00461U105 701 LEE ROAD SUIT
Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A
0001231919-26-000911.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001231919-25-000641 0001863769 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 06/30/2026 0001817229 VOR BIOPHARMA INC.
Allogene Therapeutics, Inc. filed SCHEDULE 13G/A
0001231919-26-000912.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001231919-26-000398 0001863769 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 06/30/2026 0001737287 Allogene Therapeuti
Aura Biosciences, Inc. filed SCHEDULE 13G/A
0001231919-26-000913.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001415889-25-014432 0001863769 XXXXXXXX LIVE 3 Common Stock, $0.00001 par value per share 06/30/2026 0001501796 Aura Biosciences,
Braveheart Bio, Inc. filed SCHEDULE 13G
0001231919-26-000910.txt : 20260814 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001863769 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 08/07/2026 0002131524 Braveheart Bio, Inc. 10567X101 One Letterman
Attovia Therapeutics, Inc. filed SCHEDULE 13D
, as amended; or (j) Any action similar to any of those enumerated above. The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes ther
Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13D/A
0001231919-26-000851.txt : 20260810 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-24-223402 0001863769 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value per share 08/06/2026 false 0001776111 55287L101 MB